Company: MBIO
Filing Date: 2025-04-01
Form Type: 424B3
Source: 0001104659-25-030657
Chunk: 114

Company: MUSTANG BIO, INC.
Filing Date: 2025-04-01
Form: 424B3
Chunk 114
---
 about our equity compensation plans
is incorporated herein by reference to Part III, Item 12 of this Form 10-K.

Holders of Record

As of March 26, 2025, there were approximately
fifty-seven holders of record of our common stock and one holder of record for our Class A common stock. The actual number of holders
of our common stock is greater than this number of record holders and includes stockholders who are beneficial owners, but whose shares
are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares
may be held in trust by other entities.

Dividends

We have never paid or declared any cash dividends
on our common stock, and we do not anticipate paying any cash dividends on our common stock in the foreseeable future. We intend to retain
all available funds and any future earnings to fund the development and expansion of our business. Any future determination to pay dividends
will be at the discretion of our Board and will depend upon a number of factors, including our results of operations, financial condition,
future prospects, contractual restrictions, restrictions imposed by applicable law and other factors our Board deems relevant.

Recent Sales of Unregistered Securities

The following list sets forth information as to
all unregistered securities we have sold since January 1, 2024, through the date of this Form 10-K:

​

June 2024 Private Placement

On June 19, 2024, we entered into a purchase
agreement (the “June 2024 Purchase Agreement”) with an institutional accredited investor, for the issuance and sale of
warrants (the “June 2024 Warrants”) to purchase up to 122,600 shares of our common stock. Pursuant to the June 2024
Purchase Agreement, we agreed to issue and sell the June 2024 Warrants at an offering price of $20.50 per warrant to purchase one
share of common stock. The June 2024 Warrants have an exercise price of $20.50 per share (subject to adjustment as set forth in the

<div align='center'>59</div>

​

Table of Contents

June 2024 Warrants), were exercisable immediately
upon issuance and will expire five and one-half (5.5) years from the date on which the June 2024 Warrants become exercisable.
The June 2024 Warrants contain standard anti-dilution adjustments to the exercise price including for share splits